

# Resource Summary Report

Generated by RRID on Jul 29, 2026

## Brilliant Violet 510(TM) anti-human CD3

RRID:AB\_2563468

Type: Antibody

### Proper Citation

BioLegend Cat# 300448, RRID:AB\_2563468

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2563468](http://antibodyregistry.org/AB_2563468)

**Proper Citation:** BioLegend Cat# 300448, RRID:AB\_2563468

**Target Antigen:** CD3

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: FC

**Antibody Name:** Brilliant Violet 510(TM) anti-human CD3

**Description:** This monoclonal targets CD3

**Target Organism:** human

**Clone ID:** Clone UCHT1

**Antibody ID:** AB\_2563468

**Vendor:** BioLegend

**Catalog Number:** 300448

**Alternative Catalog Numbers:** 300447

**Record Creation Time:** 20250820T063236+0000

**Record Last Update:** 20250821T002338+0000

### Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 510(TM) anti-human CD3.

No alerts have been found for Brilliant Violet 510(TM) anti-human CD3.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 18 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Liu SX, et al. (2025) Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma. Cell reports. Medicine, 6(7), 102200.

Morton JJ, et al. (2025) Autologous Thymic Organoids Support Functional T-cell Education and Enhance Antitumor Immunity in Humanized Mice with Melanoma Xenografts. Cancer research communications, 5(11), 2053.

Zhang L, et al. (2025) KLRG1 re-defines a leukemic clone of CD8 effector T cells sensitive to PI3K inhibitor in T cell large granular lymphocytic leukemia. Cell reports. Medicine, 6(4), 102036.

Ma R, et al. (2024) Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell reports. Medicine, 5(7), 101628.

MacDonald L, et al. (2024) Synovial tissue myeloid dendritic cell subsets exhibit distinct tissue-niche localization and function in health and rheumatoid arthritis. Immunity, 57(12), 2843.

Prokhnevskaya N, et al. (2023) CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity, 56(1), 107.

Ma K, et al. (2023) CEA cell adhesion molecule 5 enriches functional human hematopoietic stem cells capable of long-term multi-lineage engraftment. iScience, 26(12), 108561.

Santegoets SJ, et al. (2023) The combined HPV16-E2/E6/E7 T cell response in oropharyngeal cancer predicts superior survival. Cell reports. Medicine, 4(11), 101262.

Chan KL, et al. (2022) Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses. Cancer cell, 40(10), 1190.

Reuschl AK, et al. (2022) HIV-1 Vpr drives a tissue residency-like phenotype during selective infection of resting memory T cells. *Cell reports*, 39(2), 110650.

Mathewson ND, et al. (2021) Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. *Cell*, 184(5), 1281.

Pušnik J, et al. (2021) Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4+ T cell help. *Cell reports*, 35(13), 109320.

Bergamaschi L, et al. (2021) Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. *Immunity*, 54(6), 1257.

Caduff N, et al. (2021) KSHV infection drives poorly cytotoxic CD56-negative natural killer cell differentiation in vivo upon KSHV/EBV dual infection. *Cell reports*, 35(5), 109056.

Szabo PA, et al. (2021) Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. *Immunity*, 54(4), 797.

Martinez-Fabregas J, et al. (2020) CDK8 Fine-Tunes IL-6 Transcriptional Activities by Limiting STAT3 Resident Time at the Gene Loci. *Cell reports*, 33(12), 108545.

Dangaj D, et al. (2019) Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. *Cancer cell*, 35(6), 885.

Körner C, et al. (2017) HIV-1-Mediated Downmodulation of HLA-C Impacts Target Cell Recognition and Antiviral Activity of NK Cells. *Cell host & microbe*, 22(1), 111.